Globally, Cambrex offers a variety of technology-driven products and services that accelerate the development of small molecule therapeutics from custom development to commercial manufacturing, including advanced chemical synthesis, enzymatic biotransformations, high potency APIs, high energy chemistry, controlled substances and formulation of finished dosage form products.
In this webinar, the speakers will examine how Cambrex works with large, mid-size, emerging and niche pharmaceutical companies to meet their changing small molecule needs and bring their products to market quickly.
Joe Nettleton, VP of Operations and Site Director, Cambrex Charles City
Joe Nettleton is the Vice President of Operations for Cambrex Charles City. He has been overseeing the Cambrex Charles City site since 2004.
Bjarne Sandberg, Managing Director, Cambrex Karlskoga
Bjarne Sandberg is the Managing Director of Cambrex Karlskoga. He has been overseeing the Cambrex Karlskoga site since 2013. Prior to that, he was responsible for business improvements and finance for Cambrex Karlskoga.
Who Should Attend?
Sourcing & procurement managers, Project managers, Supplier managers, Contract manufacturing managers, R&D Chemists, Analytical Chemists, CEOs
Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics. The Company offers Active Pharmaceutical Ingredients (APIs), advanced intermediates and enhanced drug delivery products for branded and generic Pharmaceuticals. Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis, controlled substances and formulation of finished dosage form products.